"While genome mutations and recombinations of DNA viruses like HAdVs are less common than observed for RNA viruses, when they do occur, the resultant virus may be a new and different pathogen," stated Dr. Donald Seto, Professor in the School of Systems Biology at GMU. "With whole genome sequencing provided by BGI, we will be able to answer how these viruses change over time, including how fast, enabling researchers to identify emerging pathogens, develop effective treatments, including vaccines, and begin to understand how to predict pathogens."
Included among the investigators are scientists working at the School of Systems Biology at GMU, the Department of Ophthalmology at Mass. Eye and Ear and the Department of Microbiology and Immunology at OUHSC.
"We welcome this opportunity to work with this consortium and its global collaborators on the sequencing of 100 human adenoviruses," stated Yingrui Li, Vice Director of BGI. "By applying BGI's state-of-the-art whole genome sequencing and analysis to these HAdVs, we believe we will make a significant contribution to identifying the evolution of adenovirus mutations and recombinations, and to an increased understanding of the genomic basis of their disease effects in humans."
All intellectual property resulting from this project will be shared by BGI, Mass. Eye and Ear, OUHSC, GMU and their collaborators. Upon completion of the sequencing and analysis of the 100 HAdVs, the findings will be co-authored by all in a paper to be published in a peer-reviewed scientific journal.
|Contact: Jia Liu|